Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,491 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Thorax Clear all

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: BMS-986442, Nivolumab, Docetaxel, Carboplatin, Pemexetred, Paclitaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • Costa Mesa, California • Orange, California + 11 more

Conditions: Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions: Not listed
Lead sponsor: Fresh Medical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer
Interventions: mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 2
States / cities: Bethesda, Maryland • Nashville, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Sutetinib Maleate Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Glendale, California • La Jolla, California • Tampa, Florida + 7 more

Conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer
Interventions: ponatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more

Conditions: Small Cell Lung Cancer
Interventions: RAD001 (everolimus); Drug
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 19
States / cities: Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 11 more

Conditions: Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy, Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Radiation · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions: Sacituzumab Govitecan-hziy (SG); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 12
States / cities: Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more

Conditions: Ovarian Cancer, Nonsmall Cell Lung Cancer
Interventions: XMT-1592; Biological
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions: Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Recurrent Small Cell Lung Cancer
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, motesanib diphosphate, pharmacological study; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 19
States / cities: Birmingham, Alabama • Beverly Hills, California • Farmington, Connecticut + 16 more

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 80
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
Interventions: DR-0202; Drug
Lead sponsor: Dren Bio; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more

Conditions: Solid Tumor
Interventions: Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more

Conditions: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer, Genito Urinary Cancer, Gastrointestinal Cancers
Interventions: Comparison of HyperSight CBCT imaging to conventional CBCT imaging.; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Columbus, Ohio

Conditions: Cancer, Tumor, Solid, Cancer, Lung, Cancer, Bone, Metastasis to Lung, Metastasis to Bone
Interventions: RMRS IDE Device; Device
Lead sponsor: RefleXion Medical; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Stanford, California • Dallas, Texas

Conditions: High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Interventions: BMS-986463; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Hackensack, New Jersey • Columbus, Ohio + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: imetelstat, Bevacizumab; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 23 more

Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions: Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more

Search by objective public record fields.

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Collection of Blood From Patients With Cancer

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Feasibility Study of CBCT for IGRT in Cancer Patients

Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.